CS
Chris Shibutani Goldman Sachs Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Vaxcyte
PCVX
$4.15B
| $32 | $100 |
213%
upside
| Buy |
1 Apr ‘25
5 months ago |
|
2
Erasca
ERAS
$440M
| $1.55 | $3 |
94%
upside
| Buy |
21 Mar ‘25
5 months ago |
|
3
Seres Therapeutics
MCRB
$154M
| $17.59 | $15 |
15%
downside
| Sell |
14 Mar ‘25
6 months ago |
|
4
Alkermes
ALKS
$4.45B
| $26.93 | $32 |
19%
upside
| Buy |
14 Feb ‘25
6 months ago |
|
5
BioNTech
BNTX
$24.3B
| $101 | $137 |
36%
upside
| Buy |
8 Nov ‘24
10 months ago |
|
6
Syndax Pharmaceuticals
SNDX
$1.36B
| $15.73 | $33 |
110%
upside
| Buy |
7 Nov ‘24
10 months ago |
|
7
United Therapeutics
UTHR
$17.9B
| $396.50 | $302 |
24%
downside
| Neutral |
1 Nov ‘24
10 months ago |
|
8
Royalty Pharma
RPRX
$15.6B
| $36.18 | $51 |
41%
upside
| Buy |
14 Aug ‘24
1 year ago |
|
9
Johnson & Johnson
JNJ
$423B
| $175.79 | $155 |
12%
downside
| Neutral |
19 Jul ‘24
1 year ago |
|
10
Amylyx Pharmaceuticals
AMLX
$1.05B
| $11.83 | $4 |
66%
downside
| Neutral |
12 Jul ‘24
1 year ago |
|
11
Organon & Co
OGN
$2.67B
| $10.26 | $20 |
95%
upside
| Neutral |
6 May ‘24
1 year ago |
|
12
Eli Lilly
LLY
$676B
| $754.62 | $723 |
4%
downside
| Neutral |
11 Apr ‘24
1 year ago |
|
13
Schrodinger
SDGR
$1.34B
| $18.15 | $26 |
43%
upside
| Neutral |
1 Mar ‘24
1 year ago |
|
14
Neurocrine Biosciences
NBIX
$14B
| $141.25 | $153 |
8%
upside
| Buy |
25 Jan ‘24
1 year ago |
|
15
AbbVie
ABBV
$374B
| $211.64 | $173 |
18%
downside
| Buy |
11 Dec ‘23
1 year ago |
|
16
Bristol-Myers Squibb
BMY
$96B
| $47.15 | $69 |
46%
upside
| Buy |
30 Oct ‘23
1 year ago |
|
17
Innoviva
INVA
$1.25B
| $19.87 | $13 |
35%
downside
| Neutral |
3 Mar ‘23
2 years ago |
|
18
Revolution Medicines
RVMD
$7.56B
| $40.45 | $23 |
43%
downside
| Neutral |
1 Mar ‘23
2 years ago |
|
19
Nektar Therapeutics
NKTR
$916M
| $48.18 | $30 |
38%
downside
| Sell |
27 Feb ‘23
2 years ago |
|
20
Ventyx Biosciences
VTYX
$169M
| $2.37 | $50 |
2,010%
upside
| Buy |
19 Dec ‘22
2 years ago |
|
21
Kymera Therapeutics
KYMR
$3.11B
| $43.48 | $52 |
20%
upside
| Buy |
16 Dec ‘22
2 years ago |
|
22
Pfizer
PFE
$140B
| $24.57 | $60 |
144%
upside
| Buy |
13 Dec ‘22
2 years ago |
|
23
Entrada Therapeutics
TRDA
$199M
| $5.22 | $18 |
245%
upside
| Neutral |
8 Nov ‘22
2 years ago |
|
24
Tango Therapeutics
TNGX
$708M
| $6.36 | $17 |
167%
upside
| Buy |
7 Sep ‘21
4 years ago |
|